Tags

Type your tag names separated by a space and hit enter

Summary of clinical trials with zafirlukast.
Am J Respir Crit Care Med. 1998 Jun; 157(6 Pt 2):S238-45; discussion S245-8.AJ

Abstract

Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function without increasing the number of adverse events. Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma.

Authors+Show Affiliations

Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pennsylvania 15261, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9647606

Citation

Calhoun, W J.. "Summary of Clinical Trials With Zafirlukast." American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 6 Pt 2, 1998, pp. S238-45; discussion S245-8.
Calhoun WJ. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med. 1998;157(6 Pt 2):S238-45; discussion S245-8.
Calhoun, W. J. (1998). Summary of clinical trials with zafirlukast. American Journal of Respiratory and Critical Care Medicine, 157(6 Pt 2), S238-45; discussion S245-8.
Calhoun WJ. Summary of Clinical Trials With Zafirlukast. Am J Respir Crit Care Med. 1998;157(6 Pt 2):S238-45; discussion S245-8. PubMed PMID: 9647606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Summary of clinical trials with zafirlukast. A1 - Calhoun,W J, PY - 1998/7/1/pubmed PY - 1998/7/1/medline PY - 1998/7/1/entrez SP - S238-45; discussion S245-8 JF - American journal of respiratory and critical care medicine JO - Am J Respir Crit Care Med VL - 157 IS - 6 Pt 2 N2 - Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function without increasing the number of adverse events. Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/9647606/Summary_of_clinical_trials_with_zafirlukast_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=9647606.ui DB - PRIME DP - Unbound Medicine ER -